Article
Two-year adjuvant imatinib mesylate after complete resection of localized, high-risk GIST with KIT exon 11 mutation.
Cancer chemotherapy and pharmacology - 1 Jan 2013
Kang Yoon-Koo, Kang Byung Woog, Im Seock-Ah, Lee Jae-Lyun, Park Sook Ryun, Kang Won Ki, Chang Heung Moon, Kim Tae Won, Oh Do-Youn, Jung Kyung Hae, Ryu Min-Hee
Abstract excerpt
PURPOSE: To evaluate the efficacy and safety of 2-year adjuvant imatinib for patients at high risk of recurrence after complete resection of localized gastrointestinal stromal tumor with KIT exon 11 mutation. METHODS: Imatinib 400 mg/d was administered until disease recurrence, intolerable toxicities, or for 2 years. The primary end point was recurrence-free survival. RESULTS: Patients (n = 47) from 4 centers in...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.